Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Renzoni, A. de Lauretis, P. Pantelidis, P. Sestini, N. Goh, R. Hoyles, C. Zappala, C. P. Denton, D. J. Abraham, P. Kelleher, R. M. du Bois, D. M. Hansell, S. A. Clark, A. U. Wells (London, United Kingdom; Rome, Siena, Italy; Brisbane, Australia; Denver, United States Of America). Serum interleukin 6 levels predict disease progression in scleroderma-associated interstitial lung disease. Eur Respir J 2010; 36: Suppl. 54, 5662

Member's Comments

No comment yet.

Related content which might interest you: Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Elevation of serum tumor markers in patients with interstitial lung disease Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005 IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2007; 30: Suppl. 51, 373s Year: 2007 Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Serum KL-6 as a biomarker to assess response to azathioprine in connective tissue disease associated lung disease (CTD-ILD) Source: International Congress 2015 – Connective tissue disorders Year: 2015 Serum CCL18 is predictive for lung disease progression and mortality in systemic sclerosis Source: Eur Respir J 2014; 43: 1530-1532 Year: 2014 Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis Source: Eur Respir J 2011; 38: 1355-1360 Year: 2011 KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 IL-6 and IL-8 in stable and exacerbated IPF patients and their association to outcome Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Osteopontin and interleukin-6 as biomarkers of interstitial lung disease Source: Virtual Congress 2020 – Intercellular communication in tissue remodelling of chronic lung diseases Year: 2020 The Gender-Age-Physiology (GAP) Index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD). Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 TNF-alpha, IL-8, IL-6 levels in serum of sarcoidosis patients with different clinical course Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013 C-reactive protein and serum amyloid A overexpression in lung tissues of chronic obstructive pulmonary disease patients Source: Annual Congress 2012 - Inflammatory mechanisms in COPD Year: 2012 Differences in cellular expression of C-reactive protein and serum amyloid A in lung tissue in patients with chronic obstructive pulmonary disease Source: Annual Congress 2012 - Inflammatory mechanisms in COPD Year: 2012 Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study. Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021 Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Plasma mitochondrial DNA as a biomarker of disease progression in idiopathic pulmonary fibrosis Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias Year: 2018 Endotrophin is related to disease progression in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020